Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2012

View Archived Issues

Allergan patents novel lysophospholipid receptor ligands

New aminotransferase inhibitors prepared by Pfizer

Phase Ia trial assesses AGS-009 in patients with SLE

Scientists link new mutations to orofacial clefts and cancer risk

Melatonin MT2 receptor agonist shows promise to treat sleep-related disorders

Dainippon Sumitomo Pharma discloses novel anti-CD81 antibodies

Lilly designs new mGlu5 receptor antagonists

Early-stage clinical results disclosed on prodrug for cancer

Esteve divulges novel sigma1-receptor ligands

Mologen enters agreement for MIDGE-based gene therapy

Novel agents for neurodegenerative diseases discovered in Japan

Merck Serono and Compugen form new biomarker company

Janssen submits NDA for tuberculosis drug with new mode of action

NuPathe to resubmit NDA for migraine patch

AstraZeneca and Cellworks to design combination therapies for drug-resistant tuberculosis

The Medicines Company gives update on cangrelor trial enrollment

New diagnostics for cancer prepared by GE Healthcare

Rexahn submits IND application for RNA helicase p68 inhibitor

Momenta Pharmaceuticals begins dosing in metastatic pancreatic cancer study

New compounds for cancer developed in Canada

Milatuzumab evaluated in elderly patients with chronic lymphocytic leukemia

Ono to conduct first-in-human trial of peptide-cocktail cancer vaccine

Enrollment begins in phase III Kyprolis trial

Cerulean updates on its lead nanopharmaceutical anticancer candidate

Zonisamide monotherapy approved in E.U., application for pediatric use under review

FDA issues new drug safety communication regarding Zofran

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...